- Open Access
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Alzheimer's Research & Therapy volume 9, Article number: 85 (2017)
- The Correction to this article has been published in Alzheimer's Research & Therapy 2018 10:73
This commentary discusses the implications of disease-modifying treatments for Alzheimer’s disease which seem likely to appear in the next few years and results from a meeting of British experts in neurodegenerative diseases in Edinburgh. The availability of such treatments would help change public and professional attitudes and accelerate engagement with the prodromal and preclinical populations who might benefit from them. However, this would require an updated understanding of Alzheimer’s disease, namely the important distinction between Alzheimer’s disease and Alzheimer’s dementia.
Since treatments are likely to be most effective in the early stages, identification of clinically relevant brain changes (for example, amyloid burden using imaging or cerebrospinal fluid biomarkers) will be crucial. While current biomarkers could be useful in identifying eligibility for new therapies, trial data are not available to aid decisions about stopping or continuing treatment in clinical practice. Therefore, effective monitoring of safety and effectiveness when these treatments are introduced into clinical practice will be necessary to inform wide-scale use. Equity of access is key but there is a tension between universal access for everyone with a diagnosis of Alzheimer’s disease and specifying an eligible population most likely to respond. We propose the resources necessary for an optimal care pathway as well as the necessary education and training for primary and secondary care.
The majority of current services in the UK and elsewhere would not be able to accommodate the specialist investigations required to select patients and prescribe these therapies. Therefore, a stepped approach would be necessary: from innovating sentinel clinical-academic centres that already have capacity to deliver the necessary phase IV trials, through early adoption in a hub and spoke model, to nationwide adoption for true equity of access. The optimism generated by recent and anticipated developments in the understanding and treatment of Alzheimer’s disease presents a great opportunity to innovate and adapt our services to incorporate the next exciting development in the field of dementia.
Driven by population ageing, dementia is now recognised as one of the greatest global public health challenges [1, 2]. The commonest aetiology of the dementia syndrome is Alzheimer’s disease. Currently, only symptomatic treatments for Alzheimer’s dementia are available and, as yet, the findings from therapeutic trials for drugs and biological agents to modify the course of Alzheimer’s disease before dementia develops are universally negative . However, almost 100 treatments are currently being investigated, often targeting individuals earlier in the disease process , and very promising phase II work has been published . Given ongoing research efforts, it seems likely that interventions—be they pharmacological or non-pharmacological multi-modal interventions—will be available in the near future for people diagnosed with prodromal dementia. This would fundamentally transform how the condition is perceived, diagnosed, and managed.
Even before the full dementia syndrome is present, Alzheimer’s disease may manifest as changes in biomarkers (‘preclinical’ disease) or minor cognitive symptoms (‘prodromal’ disease or ‘mild cognitive impairment’) [6, 7]. These pre-dementia stages of illness rely heavily on the understanding of an individual’s burden of disease measured using biomarkers found in cerebrospinal fluid (CSF) and through metabolic brain imaging. Consequently, any future selection of patients for treatment will require the ability to demonstrate such biomarker ‘abnormalities’ in contrast to the relatively simple clinical assessments needed to initiate cholinesterase inhibitors. This would require access to PET imaging or CSF sampling for patient selection for treatment rather than the relatively simple clinical assessments needed to initiate the current symptomatic treatments for Alzheimer’s disease. This is an exciting prospect but how such a transformation could be implemented in the UK National Health Service (NHS) is unclear.
To address this lack of clarity, a group of academic clinicians from neurology, psychiatry, and neuroradiology disciplines and charity representatives met in Edinburgh to discuss how the NHS and other health care providers could respond to the future availability of a disease-modifying treatment for Alzheimer’s disease and what the role of biomarkers would be in the diagnostic process. The group discussed the implications for existing clinical services and the best way to adapt services to deliver the most appropriate and equitable access to such therapeutic advances. The overall purpose of the meeting and this report was to inform the predictable evolution in services, attitudes, and understanding by clarifying the changes to services, resource allocation, training, and public awareness that will be necessary. If implemented now, our message (Box 1) would also bring tangible benefits to people currently being referred to dementia services.
The group met once and was led through a pre-specified agenda by the three co-chairs MNR, AB, and CWR. The agenda covered the current use of and the science behind imaging and other biomarkers, the current pipeline of disease-modifying therapies for Alzheimer’s disease, and a review of current care pathways in the UK. The meeting was minuted by TCR and, before the conclusion of the meeting, the statements for this consensus statement were discussed and unanimously agreed by all present. Each co-author has contributed to the final drafting of this manuscript, thereby endorsing the views and proposals herein.
Biomarkers for assessment and diagnosis
Treatments are likely to be most effective in the early stages of Alzheimer’s disease
Alzheimer’s disease begins as early as mid-life and only manifests as Alzheimer’s dementia once the disease is at an advanced stage [8, 9]. Therefore, Alzheimer’s disease is generally far advanced by the time Alzheimer’s dementia is diagnosed, even at an “early” stage of dementia. There is an emerging consensus that optimal disease modification would be best achieved at earlier stages of the disease before dementia develops. Multiple failed phase III trials (most recently solanezumab and verubecestat ) seem to support this. Although stage of disease may have mediated trial failure, other possibilities include insensitive outcome measures, poor target engagement, heterogeneity of sample across multiple sites and languages, insufficient phase II data informing phase III confirmation, and the possibility that the specific targeting of the amyloid pathway is inadequate to generate clinical benefit.
Thus, future treatments will be initially offered to people with mid-stage Alzheimer’s disease but without symptoms sufficiently severe to merit a diagnosis of dementia, i.e. prodromal Alzheimer’s disease (Fig. 1). Eventually, treatments might be offered to people at an even earlier stage: people with biomarker evidence of Alzheimer’s disease but minimal or no symptoms, i.e. preclinical Alzheimer’s disease. There are several preclinical trials ongoing and this is the primary focus of the European Prevention of Alzheimer’s Dementia (EPAD) Consortium (http://ep-ad.org/) .
Markers of cortical amyloidosis are fundamental
Treatment of Alzheimer’s dementia is currently ‘one size fits all’ with anyone with the clinical syndrome being considered for a cholinesterase inhibitor or memantine . However, since early disease-modifying treatments for Alzheimer’s disease are likely to target amyloid aggregation—although tau-focused therapies are also in development—markers of cortical pathology such as amyloidosis will become central in assessing eligibility for new treatments. This drive towards molecular-based therapeutics will inevitably lead to molecular-based diagnostics. This would move the field towards precision medicine, allowing us to offer targeted treatments to individuals with cortical amyloidosis with the prospect of even greater precision in the future.
Therefore, markers of cortical pathology such as amyloidosis will become central in diagnosing Alzheimer’s disease—particularly at a preclinical stage—and in assessing eligibility for the new treatments. All current trials enrich the clinical sample recruited for the presence of cortical amyloidosis and it is highly likely that these selection criteria will be used to access the treatment in clinical practice.
Cerebral amyloidosis can be measured directly using amyloid PET imaging or indirectly in CSF. There is high concordance between these diagnostic approaches , so local availability, cultural factors, and staff experience will determine the choice between the two.
The use of biomarkers for personalising intervention and for gauging response
In a research setting, PET-Amyloid Imaging, CSF Aβ42, tau, and p-tau are useful biomarkers to differentiate people with Alzheimer’s dementia from controls . However, the current utility of these biomarkers in a clinical context, given the low specificity of these tests (e.g. CSF Aβ) for Alzheimer’s dementia in the elderly and the inconsistent quality of the evidence base is less clear [15, 16]. Eligibility criteria for new disease-modifying treatments would initially need to echo the entry criteria for the phase III trials for the treatment, all of which now include a marker of amyloid burden. Further enrichment of the clinical population using APOE status should only be recommended in clinical practice where there was a demonstrable pharmacogenetic effect noted in the treatment’s licensing trial (either for efficacy or safety) unless new evidence emerges for its utility in risk prediction models.
Early disease-modifying treatments will probably slow, rather than reverse, neurodegeneration and so on-going treatment may be required to maintain this effect. Treatment might be lifelong and last several decades. However, there are currently no reliable and validated patient-related outcome instruments for the early stages of the disease. To ensure ongoing clinical and cost-effectiveness, explicit and early stopping criteria would be important, which will require a surrogate biomarker response (Fig. 2). However, no biomarker currently studied is known to be suitable for this purpose and current trials (except DIAN-TU ) use intermediary biomarker phenotypes such as PET-Amyloid to determine if a treatment is futile. Furthermore, since clinical trials assess this at a group level and not for individuals, one would only be able to derive a probability of a lack of long-term success for an individual in clinical practice. Therefore, there is currently no reliable way to decide whether an individual should stop or continue other than on the grounds of safety. Embedding this outcome into phase II and III trials would facilitate greater appropriate access to therapies by minimizing inappropriate, ineffective use, but the limited duration of these trials (up to two years) would be a challenge.
Accessing the vast amount of observational data being gathered through programmes like the European Medical Information Framework (EMIF) and Dementias Platform UK (DPUK) will give an indication of the expected rate of changes in sub-populations—though direct comparison of these data with randomised, controlled trial data would be problematic from a statistical perspective. Phase IV testing—as advocated below—would address some of these issues as would the use of readiness cohorts (e.g. EPAD) that can use run-in data from the same population as the trial to help guide expected placebo declines in the trial population.
The importance of phase IV testing
Substantial post-marketing research must be carried out before disease-modifying therapies are widely used and this should be co-produced by the public sector, charities, and industry alongside agreements on pricing and reimbursement that reflect optimum value for the NHS and patients. This would encompass accumulation of safety data as well as real world experience on mid- to long-term patient outcomes (including patient-related outcome measures), compliance, service impact, health economics, and longitudinal biomarker analysis to assist the establishment of a response biomarker. Generic phase IV protocols must be developed before these drugs are marketed so they can be safely and effectively introduced as widely as possible. This will involve close co-operation with bodies such as the National Institute for Health and Care Excellence (NICE), which approves the use of new treatments in the English and Welsh National Health Service and has major influence elsewhere. The establishment of better systems for gathering information from clinical practice would ease this phase IV testing if routinely collected electronic data contained phenotypic, clinical, and resource utilisation variables relevant to brain health in order to undertake large scale, standing phase IV work.
Policy and professional development
Equity of access is key
New treatments will initially be provided to patients in whom their use will be clinically and cost-effective and it is vital that when a new treatment becomes available it can be offered to everyone who is eligible. However, there is an inherent tension between specifying the eligible population through biomarkers (not to mention the uneven spread of tertiary-level expertise in dementia diagnosis and treatment) and equity of access—for example, for people of all ages, from all ethnic groups and from all localities. Patient and public engagement will be important to ensure that treatment provision is not perceived as inequitable.
In the first instance, prescription of disease-modifying treatments may only be possible in centres with capacity to undertake the partner diagnostic work as well as monitoring for safety issues and undertaking the phase IV work described above. Nevertheless, within these centres (which should act as regional hubs for prescribing) equity of access should be mandated and monitored, and access extended as quickly as possible. Close regional collaboration across NHS trust boundaries will be essential to this.
Professionals will need specific training
There will need to be substantial education and training provided for primary and secondary care professionals about new disease-modifying treatment for Alzheimer’s disease. In primary care this would need to focus on early symptoms and risk factors to ensure timely referral whereas in secondary care it would cover the safe and effective use of biomarkers. Indeed, surveying current provision of dementia services and knowledge and attitudes should be done immediately to assess current service capacity and identify training needs. This could build on the existing Memory Services National Accreditation Programme (MSNAP) in England and Wales.
The UK has an established pool of clinical academics who already use these interventions in clinical trials as well as PET imaging and CSF biomarkers, either routinely or on selected patients in their clinical practice or research. However, further planning will be important and necessary to ensure this knowledge and expertise can be shared with all relevant staff groups across the NHS who will be operating from a diversity of clinical settings and backgrounds.
This is an opportunity to reconfigure our services
Even without formal assessment of national and regional capacity, it is clear that increased access to neuroimaging and CSF analysis would be needed to support the additional diagnostic processes required for the appropriate targeting of new treatments. An agreed optimal care pathway would minimize idiosyncratic and inefficient practice. Initially rolled out in centres with relevant resources and expertise (forming a Brain Health Clinic Network), the resulting real world experience could be used to develop pathways for broader adoption throughout the NHS.
Dementia services are currently run under a predominantly psychiatric model of care with a symptomatic and palliative focus. However, a reconfigured service would require seamless collaboration between disciplines, patient groups, and specialties in order to expand the dementia-focussed clinical services to include an Alzheimer’s disease and pre-dementia service for cognitively healthier, younger patients. Indeed, engagement with other specialties who may be in contact with such patients because of other health conditions will be an important necessary development. The focus would be on maintaining brain health using risk reduction, resilience building, molecular-based diagnostics, and delivering complex pharmaceutical interventions.
The optimal care pathway
Who should be referred?
Many people—including those already diagnosed and not yet diagnosed with Alzheimer’s disease—would probably present to their GP when the marketing of a disease-modifying treatment was covered in the media. This has substantial resource implications for an already busy workforce. The number of specialists with relevant experience and appropriate facilities for diagnosis and treatment will represent important limitations.
Memory services currently see patients with later prodromal disease and early dementia but, over time, the profile of patients would also include preclinical and early prodromal populations. The future role of the GP as gatekeeper in general is uncertain  but direct access to a diagnostic and therapeutic service for Alzheimer’s disease may not be feasible or desirable. With treatment likely to involve complex eligibility assessment, including biomarkers, one could advocate GPs referring everyone with suspected Alzheimer’s disease to a specialist service. However, only a relatively small proportion of these people referred would meet the eligibility criteria for a new treatment. On the other hand, while many people currently present with moderate or severe dementia, in the future, hopefully the majority of people will be diagnosed much earlier, even in the prodromal/preclinical stages. Better cognitive tests for use in primary care with improved specificity and sensitivity for Alzheimer’s disease to help with referral decisions are currently in development. This would support primary care triage of patients into secondary care. However, until such tests exist, selection for treatment with disease-modifying therapies could only take place in specialist centres.
What would an optimal specialist service require?
Disease-modifying therapies will be specific to Alzheimer’s disease and so there will be an even greater need to sub-type neurodegenerative diseases accurately. For this diagnostic process, access to a variety of imaging modalities to differentiate Alzheimer’s disease from other neurodegenerative conditions would be necessary—structural imaging (MRI, CT), FDG-PET, DAT, as well as amyloid and possibly tau PET (plus access to radiolabelled tracers)—plus neuroradiological and nuclear medicine expertise for the interpretation of these imaging modalities and their contextualisation alongside other assessments. Facilities for lumbar puncture would also be needed to ascertain cortical amyloidosis if PET imaging is not possible or acceptable to the patient.
The multidisciplinary team should include a specialist doctor; the skills of neurology, psychiatry, and geriatric medicine will all be relevant and should be represented. Furthermore, a new specialist nurse role could emerge, analogous to Macmillan nurses but with distinct skills from those already in existence. If pharmacogenetic testing (e.g. APOE ε4 status) is required for dose or subject selection, then embedding a genetic counselling service will also be required. Obviously, an appropriate setting to impart any diagnosis in a sensitive manner and to provide ongoing post-diagnostic information and support is vital. This service should be able to follow up people who have been commenced on a disease-modifying agent and should be able to escalate care in the case of adverse reactions during treatment administration. This might mean location in or near a general hospital.
A distinct approach for the preclinical, prodromal, and dementia stages of Alzheimer’s disease would be necessary. A comprehensive service could provide all these elements, but different expertise, skills, and care pathways are needed at different stages of disease. However, whether a broad, “one stop shop” is feasible or whether a tiered approach with primary, secondary (diagnostic), and tertiary (therapeutic) levels would be necessary is uncertain. In any case, transition through the service must be seamless. Furthermore, people with dementia often report that they wish services to be close to home.
That any new clinical service will have to keep pace with updates in diagnostic criteria for Alzheimer’s disease and other neurodegenerative conditions, it is noted that new criteria being proposed increasingly rely on biomarker evaluation which re-emphasises the need for clinical services to have access to and experience with biomarker testing as part of their clinical work-up.
How many people might be eligible for a new treatment?
Based on current service capacity, gradual implementation, and variable take up of the new service, the likely number of eligible patients will initially be hundreds rising to tens of thousands of people within a few years as services adapt and increased public awareness helps case ascertainment in primary care. However, data to back up this estimate and further detailed modelling are needed to inform planning and resource allocation.
Disease-modifying treatments would change the way we all think about neurodegenerative diseases and dementia
There is much confusion in many people’s minds (including the public, clinicians, and policy makers) about dementia—for example, whether it is the same as Alzheimer’s disease. Irrespective of this, most people currently think of dementia as an untreatable, progressive condition affecting older people. The advent of a disease-modifying treatment would change this perception. The view that Alzheimer’s disease can only be diagnosed in the dementia stage of the illness must be challenged as the prognostic accuracy of pre-dementia disease models improves. This is familiar territory in other branches of medicine where treatments are commonly started before there are clinical signs or symptoms. A major societal benefit of the advent of disease-modifying drugs would be the end of the perception of Alzheimer’s disease as an incurable, inevitably fatal disease of older people and its replacement with a more optimistic position with a high likelihood of modification of the disease course.
The Edinburgh Consensus group recognised the need to advocate for the changes outlined above as well as continually reviewing progress in the UK and elsewhere as science advances, care models adapt, and therapies become available. These are truly innovative and optimistic times in the understanding and treatment of earlier Alzheimer’s disease. Modifying the disease course with multimodal interventions and personalised treatment plans—including risk reduction—will soon be possible. Working closely with European and global colleagues in the academic, clinical, charitable, and commercial sectors and with patient groups will help the largest number of people access the right therapies to prevent or significantly delay the onset of Alzheimer’s dementia.
World Health Organization. Alzheimer’s Disease International: Dementia: a public health priority. Geneva: World Health Organization; 2012.
Prince M, Guerchet M, Prina M. Alzheimer’s Disease International: Policy brief for heads of government: the global impact of dementia 2013–2050. London: Alzheimer Disease International; 2013.
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9:702–16.
Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline. Alzheimers Dement. 2016;2:222–32.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–6.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92.
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.
Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol. 2006;5:87–96.
Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Is late-onset Alzheimer’s disease really a disease of midlife? Alzheimers Dement. 2015;1:122–30.
Hardy J, De Strooper B. Alzheimer’s disease: where next for anti-amyloid therapies? Brain. 2017;140:853–5.
Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S. Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project. Lancet Psychiatry. 2016;3:179–86.
Hampel H, O’Bryant SE, Castrillo JI, Ritchie CW, Rojkova K, et al. PRECISION MEDICINE--the Golden Gate for detection, treatment and prevention of Alzheimer’s disease. J Prev Alzheimers Dis. 2016;3:243–59.
Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci. 2015;36:297–309.
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–84.
Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;(6):CD008782. doi:10.1002/14651858.CD008782.pub4.
Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement. 2013;9:e96–e105.
Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8-19.
Greenfield G, Foley K, Majeed A. Rethinking primary care’s gatekeeper role. BMJ. 2016;354:i4803.
The Edinburgh Consensus has been reviewed and approved by the Faculty of Old Age Psychiatry of the Royal College of Psychiatrists and the Association of British Neurologists.
TCR is a member of both the Alzheimer Scotland Dementia Research Centre funded by Alzheimer Scotland and of the University of Edinburgh Centre for Cognitive Ageing & Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, and Medical Research Council is gratefully acknowledged for the latter. NCF and MNR are National Institute for Health Research (NIHR) senior investigators and acknowledge support from the NIHR Biomedical Research Centre (BRC) and the Queen Square Dementia BRU, the MRC Dementias Platform UK, the Leonard Wolfson Experimental Neurology Centre, Alzheimer’s Research UK and the Alzheimer’s Society.
The consensus meeting received no financial support and all attendees funded their own travel, accommodation, and subsistence. Alzheimer Scotland provided a meeting room in their national headquarters and refreshments. Lunch was provided by the University of Edinburgh.
Availability of data and materials
The authors’ main or most relevant affiliation has been recorded.
Ethics approval and consent to participate
Consent for publication
All authors have seen and approved the submitted version of the manuscript.
Bob Barber has participated in an advisory panel for Novartis on one occasion and conducted a number of pharmaceutical sponsored commercial clinical trials in Alzheimer’s disease (including Lilly, Roche and Janssen). He has a national role for NIHR NHS relating to commercial studies in dementia. Nick Fox has received research support from AVID/Lilly and has advised GSK, Lilly, Novartis and Roche; he serves on a data monitoring committee for Biogen—all payments for these activities are to UCL. Clive Holmes has attended advisory boards for Lilly pharmaceuticals. Martin Rossor serves on a safety monitoring committee for Servier and has advised Merck on patient registries. Tom Russ works within NHS Scotland with the Scottish Neuroprogressive and Dementia Network on commercial studies in dementia. All authors have completed the ICJME declaration of conflicts of interest and these are available on request.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ritchie, C.W., Russ, T.C., Banerjee, S. et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alz Res Therapy 9, 85 (2017). https://0-doi-org.brum.beds.ac.uk/10.1186/s13195-017-0312-4
- Alzheimer’s disease
- Service redesign
- Clinical trials